Oncolytic myxoma virus

The path to clinic

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Many common neoplasms are still noncurative with current standards of cancer therapy. More therapeutic modalities need to be developed to significantly prolong the lives of patients and eventually cure a wider spectrum of cancers. Oncolytic virotherapy is one of the promising new additions to clinical cancer therapeutics. Successful oncolytic virotherapy in the clinic will be those strategies that best combine tumor cell oncolysis with enhanced immune responses against tumor antigens. The current candidate oncolytic viruses all share the common property that they are relatively nonpathogenic to humans, yet they have the ability to replicate selectively in human cancer cells and induce cancer regression by direct oncolysis and/or induction of improved anti-tumor immune responses. Many candidate oncolytic viruses are in various stages of clinical and preclinical development. One such preclinical candidate is myxoma virus (MYXV), a member of the Poxviridae family that, in its natural setting, exhibits a very restricted host range and is only pathogenic to European rabbits. Despite its narrow host range in nature, MYXV has been shown to productively infect various classes of human cancer cells. Several preclinical in vivo modeling studies have demonstrated that MYXV is an attractive and safe candidate oncolytic virus, and hence, MYXV is currently being developed as a potential therapeutic for several cancers, such as pancreatic cancer, glioblastoma, ovarian cancer, melanoma, and hematologic malignancies. This review highlights the preclinical cancer models that have shown the most promise for translation of MYXV into human clinical trials.

Original languageEnglish (US)
Pages (from-to)4252-4258
Number of pages7
JournalVaccine
Volume31
Issue number39
DOIs
StatePublished - Sep 6 2013
Externally publishedYes

Fingerprint

Myxoma virus
Oncolytic Viruses
neoplasms
Neoplasms
Oncolytic Virotherapy
therapeutics
host range
viruses
Host Specificity
Poxviridae
immune response
pancreatic neoplasms
ovarian neoplasms
melanoma
Aptitude
Neoplasm Antigens
Hematologic Neoplasms
Therapeutics
Glioblastoma
clinical trials

Keywords

  • Hematological malignancies
  • Myxoma virus
  • Oncolytic virotherapy
  • Pancreatic cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Oncolytic myxoma virus : The path to clinic. / Chan, Winnie M.; Rahman, Masmudur; McFadden, Douglas.

In: Vaccine, Vol. 31, No. 39, 06.09.2013, p. 4252-4258.

Research output: Contribution to journalArticle

Chan, Winnie M. ; Rahman, Masmudur ; McFadden, Douglas. / Oncolytic myxoma virus : The path to clinic. In: Vaccine. 2013 ; Vol. 31, No. 39. pp. 4252-4258.
@article{3acb37de1fe54044b010bf782a67f983,
title = "Oncolytic myxoma virus: The path to clinic",
abstract = "Many common neoplasms are still noncurative with current standards of cancer therapy. More therapeutic modalities need to be developed to significantly prolong the lives of patients and eventually cure a wider spectrum of cancers. Oncolytic virotherapy is one of the promising new additions to clinical cancer therapeutics. Successful oncolytic virotherapy in the clinic will be those strategies that best combine tumor cell oncolysis with enhanced immune responses against tumor antigens. The current candidate oncolytic viruses all share the common property that they are relatively nonpathogenic to humans, yet they have the ability to replicate selectively in human cancer cells and induce cancer regression by direct oncolysis and/or induction of improved anti-tumor immune responses. Many candidate oncolytic viruses are in various stages of clinical and preclinical development. One such preclinical candidate is myxoma virus (MYXV), a member of the Poxviridae family that, in its natural setting, exhibits a very restricted host range and is only pathogenic to European rabbits. Despite its narrow host range in nature, MYXV has been shown to productively infect various classes of human cancer cells. Several preclinical in vivo modeling studies have demonstrated that MYXV is an attractive and safe candidate oncolytic virus, and hence, MYXV is currently being developed as a potential therapeutic for several cancers, such as pancreatic cancer, glioblastoma, ovarian cancer, melanoma, and hematologic malignancies. This review highlights the preclinical cancer models that have shown the most promise for translation of MYXV into human clinical trials.",
keywords = "Hematological malignancies, Myxoma virus, Oncolytic virotherapy, Pancreatic cancer",
author = "Chan, {Winnie M.} and Masmudur Rahman and Douglas McFadden",
year = "2013",
month = "9",
day = "6",
doi = "10.1016/j.vaccine.2013.05.056",
language = "English (US)",
volume = "31",
pages = "4252--4258",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "39",

}

TY - JOUR

T1 - Oncolytic myxoma virus

T2 - The path to clinic

AU - Chan, Winnie M.

AU - Rahman, Masmudur

AU - McFadden, Douglas

PY - 2013/9/6

Y1 - 2013/9/6

N2 - Many common neoplasms are still noncurative with current standards of cancer therapy. More therapeutic modalities need to be developed to significantly prolong the lives of patients and eventually cure a wider spectrum of cancers. Oncolytic virotherapy is one of the promising new additions to clinical cancer therapeutics. Successful oncolytic virotherapy in the clinic will be those strategies that best combine tumor cell oncolysis with enhanced immune responses against tumor antigens. The current candidate oncolytic viruses all share the common property that they are relatively nonpathogenic to humans, yet they have the ability to replicate selectively in human cancer cells and induce cancer regression by direct oncolysis and/or induction of improved anti-tumor immune responses. Many candidate oncolytic viruses are in various stages of clinical and preclinical development. One such preclinical candidate is myxoma virus (MYXV), a member of the Poxviridae family that, in its natural setting, exhibits a very restricted host range and is only pathogenic to European rabbits. Despite its narrow host range in nature, MYXV has been shown to productively infect various classes of human cancer cells. Several preclinical in vivo modeling studies have demonstrated that MYXV is an attractive and safe candidate oncolytic virus, and hence, MYXV is currently being developed as a potential therapeutic for several cancers, such as pancreatic cancer, glioblastoma, ovarian cancer, melanoma, and hematologic malignancies. This review highlights the preclinical cancer models that have shown the most promise for translation of MYXV into human clinical trials.

AB - Many common neoplasms are still noncurative with current standards of cancer therapy. More therapeutic modalities need to be developed to significantly prolong the lives of patients and eventually cure a wider spectrum of cancers. Oncolytic virotherapy is one of the promising new additions to clinical cancer therapeutics. Successful oncolytic virotherapy in the clinic will be those strategies that best combine tumor cell oncolysis with enhanced immune responses against tumor antigens. The current candidate oncolytic viruses all share the common property that they are relatively nonpathogenic to humans, yet they have the ability to replicate selectively in human cancer cells and induce cancer regression by direct oncolysis and/or induction of improved anti-tumor immune responses. Many candidate oncolytic viruses are in various stages of clinical and preclinical development. One such preclinical candidate is myxoma virus (MYXV), a member of the Poxviridae family that, in its natural setting, exhibits a very restricted host range and is only pathogenic to European rabbits. Despite its narrow host range in nature, MYXV has been shown to productively infect various classes of human cancer cells. Several preclinical in vivo modeling studies have demonstrated that MYXV is an attractive and safe candidate oncolytic virus, and hence, MYXV is currently being developed as a potential therapeutic for several cancers, such as pancreatic cancer, glioblastoma, ovarian cancer, melanoma, and hematologic malignancies. This review highlights the preclinical cancer models that have shown the most promise for translation of MYXV into human clinical trials.

KW - Hematological malignancies

KW - Myxoma virus

KW - Oncolytic virotherapy

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84882857863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882857863&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.05.056

DO - 10.1016/j.vaccine.2013.05.056

M3 - Article

VL - 31

SP - 4252

EP - 4258

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 39

ER -